Journal article 503 views
Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
Frank Stephen Hodi,
Vanna Chiarion-Sileni,
Rene Gonzalez,
Jean-Jacques Grob,
Piotr Rutkowski,
Charles Lance Cowey,
Christopher D Lao,
Dirk Schadendorf,
John Wagstaff,
Reinhard Dummer,
Pier Francesco Ferrucci,
Michael Smylie,
Andrew Hill,
David Hogg,
Ivan Marquez-Rodas,
Joel Jiang,
Jasmine Rizzo,
James Larkin,
Jedd D Wolchok
The Lancet Oncology, Volume: 19, Issue: 11, Pages: 1480 - 1492
Swansea University Author: John Wagstaff
Full text not available from this repository: check for access using links below.
DOI (Published version): 10.1016/S1470-2045(18)30700-9
Abstract
Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
| Published in: | The Lancet Oncology |
|---|---|
| ISSN: | 14702045 |
| Published: |
2018
|
| Online Access: |
Check full text
|
| URI: | https://cronfa.swan.ac.uk/Record/cronfa45943 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| College: |
Faculty of Medicine, Health and Life Sciences |
|---|---|
| Issue: |
11 |
| Start Page: |
1480 |
| End Page: |
1492 |